trending Market Intelligence /marketintelligence/en/news-insights/trending/pombtujufv-kkjg7fj5lna2 content esgSubNav
In This List

PTC Therapeutics' DMD treatment remains unapproved by US FDA

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


PTC Therapeutics' DMD treatment remains unapproved by US FDA

The U.S. Food and Drug Administration maintained its decision to reject PTC Therapeutics Inc.'s Duchenne muscular dystrophy treatment, ataluren.

Duchenne muscular dystrophy is a genetic disorder characterized by progressive muscle degeneration and weakness.

The U.S. regulator rejected the drug in October 2017, prompting PTC Therapeutics to file an appeal. The regulator's office of new drugs has reiterated the decision.

The company is required to submit additional data before the regulator can approve the medicine.